Urinary Adiponectin Excretion: A Novel Marker for ... - Diabetes

Table 1. Characteristics of control and type 2 diabetes subjects, and Spearman’s correlation coefficients between serum or urinary adiponectin levels
and cardiovascular risk factors and measures of subclinical atherosclerosis in type 2 diabetic patients
Control Type 2 diabetes Serum adiponectin Urinary adiponectin
Subjects patients p * r p † r p †
n 40 156
Sex (male: n; %) 25 (61.0) 117 (75.0) 0.017 - 0.290 < 0.001 - 0.009 0.915
Age (years) 51.9 ± 9.5 60.5 ± 7.8 < 0.001 0.327 < 0.001 0.181 0.025
BMI (kg/m²) 25.4 ± 4.6 33.1 ± 5.9 < 0.001 - 0.041 0.613 - 0.098 0.231
Waist-to-hip ratio 0.87 ± 0.09 1.02 ± 0.08 < 0.001 - 0.286 < 0.001 0.062 0.453
HDL cholesterol (mmol/l) 1.52 ± 0.42 1.17 ± 0.35 < 0.001 0.413 < 0.001 0.018 0.826
LDL cholesterol (mmol/l) 3.12 ± 0.72 2.66 ± 0.92 < 0.001 0.137 0.106 - 0.013 0.877
Triglycerides (mmol/l) ‡ 1.06 (0.80 – 1.71) 1.87 (1.19 – 2.86) < 0.001 - 0.311 < 0.001 - 0.069 0.400
Fasting plasma glucose (mmol/l) 5.06 ± 0.6 8.03 ± 2.74 < 0.001 - 0.167 0.041 0.073 0.375
HbA1c (%) 5.5 ± 0.5 7.2 ± 1.2 < 0.001 - 0.143 0.085 0.080 0.342
Creatinine clearance (ml/min) 119.3 ± 41.2 109.6 ± 40.7 0.146 - 0.223 0.011 - 0.156 0.074
Cystatin C (mg/l) 0.57 ± 0.13 0.79 ± 0.31 < 0.001 0.141 0.084 - 0.025 0.759
Albumin excretion rate (mg/24h) ‡